- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04213391
Effects of Sulforaphane in Patients With Prodromal to Mild Alzheimer's Disease
May 9, 2020 updated by: Second Affiliated Hospital, School of Medicine, Zhejiang University
Randomized,Double-blind, Placebo-controlled, Efficacy and Safety Study of Sulforaphane in Patients With Prodromal to Mild Alzheimer's Disease
In this proposed study, the investigators will evaluate the efficacy, safety and related mechanism of sulforaphane in treatment of Alzheimer's disease (AD).
The study will recruit 160 AD patients, and then these patients will be randomized to sulforaphane group or placebo group (80 patients per arm) for 24 weeks clinic trial.
Clinical efficacy and safety assessment will be done at screen/baseline, 4 week, 12 week, and 24 week.
The specific aims are to compare sulforaphane versus placebo on: clinical core symptoms; biological samples also will be collected, and stored to research related mechanisms.
During the study period, safety index including blood and urine routine, liver and kidney function, coagulation index and clinical effect index about neuropsychological scales will be recorded.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
In this proposed study, the investigators will evaluate the efficacy, safety and related mechanism of sulforaphane in treatment of AD.
The study will recruit 160 AD patients, then these patients will be randomized to sulforaphane group or placebo group (80 patients per arm) for 24 weeks clinic trial.
Clinical efficacy and safety assessment will be done at screen/baseline, 4 week, 12 week, 24 week.
The specific aims are to compare sulforaphane versus placebo on: 1) clinical core symptoms; The investigators hypothesize that (1) sulforaphane is superior to placebo in the treatment of clinical symptoms in patients with AD, measured by the ADAS-cog, MMSE Scale, Moca; (2) Biological samples will be collected, and stored so that the hypothesis sulforaphane may alter oxidative stress indexes or inflammatory biomarkers, and influence histone deacetylase inhibitor mechanism or inflammatory mechanism et al that may be significantly correlated with clinical improvement.
(3) Safety index including blood and urine routine, liver and kidney function, coagulation index and clinical effect index about neuropsychological scales will be recorded.
Study Type
Interventional
Enrollment (Anticipated)
160
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Qing-Qing tao, Ph.D
- Phone Number: +08613777820430
- Email: qingqingtao@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Recruiting
- Second Affiliated Hospital,Zhejiang University School of Medicine
-
Contact:
- Zhi-Ying Wu, MD&PhD
- Phone Number: +86-571-87783569
- Email: zhiyingwu@zju.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 1. Age range from 50 to 75 (including 50 and 75 years old), regardless of ethnic group or gender;
- 2. The subjects should be able to complete the cognitive ability measurement and other tests specified in the protocol;
- 3. Meeting the criteria for likely Alzheimer's Disease (AD) dementia (2011) by National Institute of Neurological Disorders and Strokes - Alzheimer's Disease and Related Diseases Association(NINCDS-ADRDA);
- 4. Patients with mild dementia: the total score of Mini-Mental State Examination (MMSE) : ≥22 points; Clinical Dementia Rating scale (CDR)score > or equal to 0.5 and < or equal to1;The MMSE score provides evidence of mild disease severity and the CDR-GS score indicates that the patients have noticeable amnestic (pAD) or cognitive and functional (mAD) deficits
- 5. The total score of the Hachinski Ischemic Score (HIS )was < 4.
- 6. Hamilton depression scale (17 items) total score ≤7 points;
- 7. Brain MRI shows a high likelihood of AD;
- 8. Before enrollment, patients should take a stable dose of dementia drugs (donepezil 5mg) ≥8 weeks;
- 9. The expected survival time is > 1 year;
- 10. Subjects should have a stable and reliable caregiver, or at least have frequent contact with the caregiver (at least 3 days per week and at least 2 hours per day), who will help patients participate in the whole study; Caregivers must accompany the subjects to the visit and assist in completing the relevant scale.
Exclusion Criteria:
- 1. Refuse to sign the inform consent form;
- 2. Other causes of dementia: known vascular, central nervous system infection ,Parkinson's disease, traumatic brain dementia, other physical and chemical factors; serious body disease , intracranial space-occupying lesions, endocrine system disease, such as thyroid disease, and a lack of vitamin B12, folic acid, or any other known causes of dementia.
- 3. Central nervous system diseases (including stroke, optic neuromyelitis, Parkinson's disease, epilepsy, etc.);
- 4. Obvious positive signs of nervous system examination;
- 5. Psychotic patients, including schizophrenia or other disorders with bipolar disorder, major depression or delirium;
- 6. Uncontrolled hypertension or hypotension during screening: systolic blood pressure ≥180(millimetres of mercury )mmHg or < 90mmhg, or diastolic blood pressure ≥120mmHg or < 60mmhg;
- 7. Unstable or severe diseases of the heart, lung, liver, kidney and hematopoietic system according to the judgment of the researchers;
- 8. Patients with incurable visual and auditory disorders that cannot complete neuropsychological tests and scales;
- 9. Female subjects who are positive in pregnancy test or breast-feeding and who cannot take effective contraceptive measures or have a birth plan;
- 10. Severe allergy, non-allergic drug reaction or multi-drug allergy history;
- 11. Participated in other clinical trials within 3 months before screening visit;
- 12. Taking any health care products related to brain and brain improvement currently and failing to keep the promise to stop using the above products;
- 13. Other conditions are unsuitable for participating in this study according to the judgement of researchers.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: sulforaphane group
The patients will take sulforaphane for 24 weeks, 2550mg once a day.
|
Sulforaphane take 2550mg once a day.
|
Placebo Comparator: Placebo group
The patients will take placebo for 24 weeks, 2550mg once a day.
|
Placebo take 2550mg once a day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Alzheimer's Disease Assessment Scale
Time Frame: From baseline to 24 weeks
|
The Alzheimer's Disease Assessment Scale (ADAS-cog) will be performed to test the cognition of patients at the enrollment, week 12 and week 24.
The score ranges from 0 to 75,and higher values represent a better outcome.
|
From baseline to 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alzheimer's Disease Collaborative research group-Activities of Daily Living scores.
Time Frame: From baseline to 24 weeks
|
Alzheimer's Disease Collaborative research group-Activities of Daily Living scores (ADCS-ADL) will be performed to test the activities of patients at the enrollment,week 6 and week12.The score ranges from 0 to 54,and higher values represent a better outcome.
|
From baseline to 24 weeks
|
Neuropsychiatric Inventory scores
Time Frame: baseline time to 24 weeks
|
Neuropsychiatric Inventory scores (NPI) will be performed to test the mental symptoms of patients at the enrollment and week12.The score ranges from 0 to 144,and higher values represent a worse outcome.
|
baseline time to 24 weeks
|
Mini-Mental State Examination scores
Time Frame: baseline time to 24 weeks
|
Mini-Mental State Examination scores(MMSE) will be performed to test the cognition of patients at the enrollment and week12.The score ranges from 0 to 30,and higher values represent a better outcome.
|
baseline time to 24 weeks
|
Montreal Cognitive Assessment scores
Time Frame: baseline time to 24 weeks
|
Montreal Cognitive Assessment scores (MoCA) will be performed to test the cognition of patients at the enrollment and week12.The score ranges from 0 to 30,and higher values represent a better outcome.
|
baseline time to 24 weeks
|
Clinician Interview-Based Impression of Change plus caregiver input
Time Frame: baseline time to 24 weeks
|
Clinician Interview-Based Impression of Change plus caregiver input (CIBIC-plus) is widely used in antidementia drug trials.
It comprises Likert scales for disease severity and changes, and written accounts summarizing semistructured interviews evaluating behavior, cognition, and function.
|
baseline time to 24 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oxidative stress indexes
Time Frame: At baseline and 24 week/endpoint
|
The change of Oxidative stress indexes as tested by Oxidative stress indexes detection kit
|
At baseline and 24 week/endpoint
|
Epigenetics indicators
Time Frame: At baseline and 24 week/endpoint
|
The change of Epigenetics indicators as tested by Epigenetics indicators
|
At baseline and 24 week/endpoint
|
Cytokines & Chemokines
Time Frame: At baseline and 24 week/endpoint
|
The change of Cytokines & Chemokines as tested by Cytokines & Chemokines detection kit
|
At baseline and 24 week/endpoint
|
Metabolites
Time Frame: At baseline and 24 week/endpoint
|
The change of Metabolites as tested by Metabolites detection kit
|
At baseline and 24 week/endpoint
|
RNA expression
Time Frame: At baseline and 24 week/endpoint
|
The change of RNA expression as tested by RNA expression detection kit
|
At baseline and 24 week/endpoint
|
Intestinal microflora
Time Frame: At baseline and 24 week/endpoint
|
The change of intestinal microflora as tested by Metagenomic technique
|
At baseline and 24 week/endpoint
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Lee S, Choi BR, Kim J, LaFerla FM, Park JHY, Han JS, Lee KW, Kim J. Sulforaphane Upregulates the Heat Shock Protein Co-Chaperone CHIP and Clears Amyloid-beta and Tau in a Mouse Model of Alzheimer's Disease. Mol Nutr Food Res. 2018 Jun;62(12):e1800240. doi: 10.1002/mnfr.201800240. Epub 2018 May 28.
- Hou TT, Yang HY, Wang W, Wu QQ, Tian YR, Jia JP. Sulforaphane Inhibits the Generation of Amyloid-beta Oligomer and Promotes Spatial Learning and Memory in Alzheimer's Disease (PS1V97L) Transgenic Mice. J Alzheimers Dis. 2018;62(4):1803-1813. doi: 10.3233/JAD-171110.
- Jhang KA, Park JS, Kim HS, Chong YH. Sulforaphane rescues amyloid-beta peptide-mediated decrease in MerTK expression through its anti-inflammatory effect in human THP-1 macrophages. J Neuroinflammation. 2018 Mar 12;15(1):75. doi: 10.1186/s12974-018-1112-x.
- Kim J, Lee S, Choi BR, Yang H, Hwang Y, Park JH, LaFerla FM, Han JS, Lee KW, Kim J. Sulforaphane epigenetically enhances neuronal BDNF expression and TrkB signaling pathways. Mol Nutr Food Res. 2017 Feb;61(2). doi: 10.1002/mnfr.201600194. Epub 2016 Nov 30.
- Zhao F, Zhang J, Chang N. Epigenetic modification of Nrf2 by sulforaphane increases the antioxidative and anti-inflammatory capacity in a cellular model of Alzheimer's disease. Eur J Pharmacol. 2018 Apr 5;824:1-10. doi: 10.1016/j.ejphar.2018.01.046. Epub 2018 Jan 31.
- Zhang R, Zhang J, Fang L, Li X, Zhao Y, Shi W, An L. Neuroprotective effects of sulforaphane on cholinergic neurons in mice with Alzheimer's disease-like lesions. Int J Mol Sci. 2014 Aug 18;15(8):14396-410. doi: 10.3390/ijms150814396.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 10, 2020
Primary Completion (Anticipated)
November 1, 2022
Study Completion (Anticipated)
December 1, 2022
Study Registration Dates
First Submitted
November 13, 2019
First Submitted That Met QC Criteria
December 24, 2019
First Posted (Actual)
December 30, 2019
Study Record Updates
Last Update Posted (Actual)
May 12, 2020
Last Update Submitted That Met QC Criteria
May 9, 2020
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Wulab-AD sulforaphane
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on sulforaphane
-
Johns Hopkins UniversityTemple University; State University of New York at BuffaloCompleted
-
University of OxfordQuadram Institute BioscienceRecruitingObesity | Metabolic Syndrome | Non-Alcoholic Fatty Liver DiseaseUnited Kingdom
-
Andrew ZimmermanJohns Hopkins UniversityCompleted
-
John KirkwoodCompletedMelanoma | Atypical NeviUnited States
-
Central South UniversityStanley Medical Research InstituteCompleted
-
Johns Hopkins UniversityRecruitingSkin AgingUnited States
-
Karolinska InstitutetLantmännenCompletedDiabetes Mellitus, Type 2 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BSweden
-
Xiangya Hospital of Central South UniversityUnknownFrontal Lobe Dysfunction
-
Anders Rosengren, MD PhDCompletedDiabetes Mellitus, Non-Insulin-Dependent
-
University of North Carolina, Chapel HillCompleted